- $881.28m
- $331.60m
- $54.55m
- 44
- 13
- 42
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.83 | ||
| Price to Tang. Book | 1.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 15.62 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.93% | ||
| Return on Equity | -61.17% | ||
| Operating Margin | -408.87% | ||
Financial Summary
| Year End 30th Nov | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 17.82 | 29.75 | 38.63 | 76.99 | 54.55 | 61.89 | 58.79 | 11.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Directors
- David Lacey NEC (69)
- Arthur Sands PRE (59)
- Hans Van Houte CFO (55)
- Stefani Wolff COO (59)
- Gwenn Hansen CSO (50)
- Christine Ring GCN (56)
- Pierre Beaurang OTH
- Judith Reinsdorf DRC (57)
- Clay Siegall DRC (60)
- Paul Silva DRC (54)
- Julia Gregory IND (68)
- Lori Kunkel IND (63)
- Jeffrey Tong IND (45)
- Last Annual
- November 30th, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- August 27th, 2009
- Public Since
- July 24th, 2020
- No. of Shareholders
- 8
- No. of Employees
- 286
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 76,235,594
- Address
- 1700 Owens St Ste 205, SAN FRANCISCO, 94158-0006
- Web
- https://www.nurixtx.com/
- Phone
- +1 4156605320
- Contact
- Elizabeth Wolffe
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for NRIX
Nurix Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Nurix Therapeutics Inc Earnings Release
Q3 2025 Nurix Therapeutics Inc Earnings Release
Similar to NRIX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Nurix Therapeutics share price?
As of Today at 22:23 UTC, shares in Nurix Therapeutics are trading at $11.56. This share price information is delayed by 15 minutes.
How has the Nurix Therapeutics share price performed this year?
Shares in Nurix Therapeutics last closed at $11.56 and the price had moved by -6.47% over the past 365 days. In terms of relative price strength the Nurix Therapeutics share price has underperformed the S&P500 Index by -13.67% over the past year.
What are the analyst and broker recommendations for Nurix Therapeutics?
The overall consensus recommendation for Nurix Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Nurix Therapeutics dividend yield?
Nurix Therapeutics does not currently pay a dividend.
Does Nurix Therapeutics pay a dividend?
Nurix Therapeutics does not currently pay a dividend.
When does Nurix Therapeutics next pay dividends?
Nurix Therapeutics does not currently pay a dividend.
How do I buy Nurix Therapeutics shares?
To buy shares in Nurix Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nurix Therapeutics?
As of the previous close price of $11.56, shares in Nurix Therapeutics had a market capitalisation of $881.28m.
Where are Nurix Therapeutics shares listed?
Here are the trading details for Nurix Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: NRIX
What kind of share is Nurix Therapeutics?
Based on an overall assessment of its quality, value and momentum Nurix Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nurix Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Nurix Therapeutics is $30.24. That is 161.59% above the last closing price of $11.56.
Analysts covering Nurix Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.03 for the next financial year.
Find out moreWhat is the trend in the Nurix Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nurix Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -53.62%.
As of the last closing price of $11.56, shares in Nurix Therapeutics were trading -41.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nurix Therapeutics PE Ratio?
The Nurix Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nurix Therapeutics?
Nurix Therapeutics' management team is headed by:
- David Lacey - NEC
- Arthur Sands - PRE
- Hans Van Houte - CFO
- Stefani Wolff - COO
- Gwenn Hansen - CSO
- Christine Ring - GCN
- Pierre Beaurang - OTH
- Judith Reinsdorf - DRC
- Clay Siegall - DRC
- Paul Silva - DRC
- Julia Gregory - IND
- Lori Kunkel - IND
- Jeffrey Tong - IND